Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Nasdaq Real Time Price USD

Protagenic Therapeutics, Inc. (PTIX)

Compare
0.4180
+0.1910
+(84.14%)
At close: April 3 at 4:00:00 PM EDT
0.3280
-0.09
(-21.53%)
After hours: April 3 at 7:59:59 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Garo H. Armen Ph.D. Co-Founder & Executive Chairman of the Board -- -- 1953
Dr. Alexander Kenneth Arrow C.F.A., M.D. CFO & Secretary 150k -- 1971
Dr. Andrew Slee Ph.D. Chief Operating Officer -- -- 1950
Dr. Robert Benjamin Stein M.D., Ph.D. Chief Medical Officer & Director -- -- 1951

Protagenic Therapeutics, Inc.

149 Fifth Avenue
Suite 500
New York, NY 10010
United States
212 994 8200 https://www.protagenic.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Corporate Governance

Protagenic Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 13, 2025 at 8:00 PM UTC - May 19, 2025 at 8:00 PM UTC

Protagenic Therapeutics, Inc. Earnings Date

Recent Events

March 31, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

February 27, 2025 at 12:00 AM UTC

PRE 14A: Proxy Statements

February 24, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 29, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 16, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 10, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 7, 2025 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

January 6, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

January 3, 2025 at 12:00 AM UTC

DEF 14A: Proxy Statements

December 30, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

Related Tickers

GNPX Genprex, Inc.
0.4316
+46.31%
 
APVO Aptevo Therapeutics Inc.
1.9900
+44.20%
 
SNSE Sensei Biotherapeutics, Inc.
0.3253
-11.12%
 
PCSA Processa Pharmaceuticals, Inc.
0.3125
+4.17%
 
TNFA TNF Pharmaceuticals, Inc.
0.4041
+0.02%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.2601
-11.08%
 
IBO Impact BioMedical Inc.
0.4640
-18.60%
 
CDT Conduit Pharmaceuticals Inc.
0.6854
-8.23%
 
GRI GRI Bio, Inc.
1.4400
-13.77%
 
CERO CERo Therapeutics Holdings, Inc.
0.6990
-4.12%